glp-1 agonists oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies How Does Orforglipron Advance Oral

NASH caused hepatomegaly, fibrosis, and inflammation in all mice, with aged mice showing increased heart weight, left ventricular volumes, and subtle systolic and diastolic dysfunction, thus NASH tends to worsen age-related cardiac dysfunction [37]

Helmstadter J, Frenis K, Filippou K, et al

DISCLAIMER: Compounded medications are NOT FDA-approved and differ from brand names

Int J Surg 110(3):15461555 Coelho C et al (2023) Laparoscopic adjustable gastric banding with liraglutide in adults with obesity and type 2 diabetes (GLIDE): a pilot randomised placebo controlled trial

doi: 10.1016/j.diabres.2022.109806

& Munro, V